Pharmaceutical product development; [ pharmaceutical research and development in the field of age-related diseases/disorders and degenerative diseases; pharmaceutical research and development in the field of chronic malady/disease and dysfunction; scientific research in the field of gene therapy; ] medical scientific research in the field of brain disease; medical scientific research in the field of neurological diseases; [ biotechnology research and scientific and pharmaceutical research in the antibody field; ] biological research; [ scientific research in the field of cancer disease; ] remote monitoring and quality control inspection for others of active substances in the pharmaceutical research field and scientific analysis of active substances in the pharmaceutical research field; research for quality inspection related to human hygiene management for medical research purposes; [ scientific and medical research of autoimmune disease; ] development of pharmaceutical preparations for cell therapy; stem cell collection for medical research; cell processing and culture for medical research; * pharmaceutical research and development in the field of age-related diseases, disorders and degenerative diseases; pharmaceutical research and development in the field of chronic malady, disease and dysfunction; scientific research for medical purpose in the field of gene therapy; biotechnology research; scientific research for medical purpose in the field of cancer disease; medical research of autoimmune disease; * pharmaceutical research and development in the field of inflammatory disease; pharmaceutical research and development in the field of eye disease; pharmaceutical research and development in the field of amyloidosis; * pharmaceutical * consultancy [ and information ] services relating to pharmaceutical quality control * ; providing information about pharmaceuticals research relating to pharmaceutical quality control *

Class [005]
Pharmaceutical Products

Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for activating cellular function; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of inflammatory diseases; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of degenerative brain disease; pharmaceutical preparations for the treatment of brain dysfunction; pharmaceutical preparations for the treatment of stroke; pharmaceutical preparations for the treatment of cerebrovascular disease; pharmaceutical preparations for the treatment of dementia; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders

Mark Details

Serial Number

No 79342262

Mark Type

No Service Mark

Attorney Docket Number

No T49423JD05

44D Filed

44D Current

44E filed

44E Current

66A Filed

Yes

66A Current

Yes

Current Basis

No Basis

Description of Design Search

The mark consists of the wording "ILLIMIS THERAPEUTICS", in stylized font, with the first letter "I", the letters "IMIS" and "THERAPEUTICS" in blue, the first letter "L" in light blue and the second letter "L" in yellow.

Legal History

Status Date	Action Taken
06^th Feb 2024	FINAL DECISION TRANSACTION PROCESSED BY IB
16^th Jan 2024	FINAL DISPOSITION PROCESSED
16^th Jan 2024	FINAL DISPOSITION NOTICE SENT TO IB
21^st Nov 2023	NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
16^th Oct 2023	LIMITATION FROM THE IB EXAMINED AND ENTERED
14^th Oct 2023	CASE ASSIGNED TO POST REGISTRATION PARALEGAL
14^th Oct 2023	CORRECTION UNDER SECTION 7 - PROCESSED
04^th Oct 2023	FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04^th Jul 2023	REGISTERED-PRINCIPAL REGISTER
04^th Jul 2023	NOTICE OF REGISTRATION CONFIRMATION EMAILED

ILLIMIS THERAPEUTICS

Classification Information

Class [042]Computer & Software Services & Scientific Services

Class [005]Pharmaceutical Products